This HTML5 document contains 28 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/mesh/concept/
n6http://linked.opendata.cz/resource/drugbank/drug/DB06149/identifier/wikipedia/
n5http://linked.opendata.cz/resource/drugbank/drug/DB06149/identifier/pharmgkb/
n18http://linked.opendata.cz/resource/drugbank/drug/DB06149/identifier/kegg-compound/
n12http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/drug/DB06149/identifier/kegg-drug/
n17http://linked.opendata.cz/resource/drugbank/drug/DB06149/identifier/drugbank/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n10http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n15http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06149
rdf:type
n3:Drug
n3:description
Teicoplanin is a glycopeptide antibiotic. It is a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, termed teicoplanin A3-1, a fused ring structure to which two carbohydrates (mannose and N-acetylglucosamine) are attached. The major and minor components also contain a third carbohydrate moiety, β-D-glucosamine, and differ only by the length and conformation of a side chain attached to it. [Wikipedia]
n3:generalReferences
# de Lalla F, Nicolin R, Rinaldi E, Scarpellini P, Rigoli R, Manfrin V, Tramarin A: Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother. 1992 Oct;36(10):2192-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1444298 # Bernareggi A, Borghi A, Borgonovi M, Cavenaghi L, Ferrari P, Vekey K, Zanol M, Zerilli LF: Teicoplanin metabolism in humans. Antimicrob Agents Chemother. 1992 Aug;36(8):1744-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1416858 # Yano R, Nakamura T, Tsukamoto H, Igarashi T, Goto N, Wakiya Y, Masada M: Variability in teicoplanin protein binding and its prediction using serum albumin concentrations. Ther Drug Monit. 2007 Aug;29(4):399-403. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17667792 # Pryka RD, Rodvold KA, Rotschafer JC: Teicoplanin: an investigational glycopeptide antibiotic. Clin Pharm. 1988 Sep;7(9):647-58. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2977108
n3:group
approved
n3:halfLife
70-100 hours
n3:indication
For the treatment of bacterial infections caused by susceptible microorganisms.
owl:sameAs
n9:DB06149 n12:DB06149
dcterms:title
Teicoplanin
adms:identifier
n5:PA164746244 n6:Teicoplanin n16:D02142 n17:DB06149 n18:C15820
n3:mechanismOfAction
Teicoplanin inhibits peptidoglycan polymerization, resulting in inhibition of bacterial cell wall synthesis and cell death.
n3:synonym
Teichomycin a2 factor 2 Teichomycin TEIC
n3:proteinBinding
90% to 95%
n3:synthesisReference
Emil Toma, Madeleine Ravaoarinoro, "Production and characteristics of anti-teicoplanin polyclonal antibody." U.S. Patent US5612459, issued November, 1990.
n10:hasConcept
n11:M0026325
n3:Molecular-Formula
n15:271B491A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n15:271B4919-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:J01XA02
n3:absorption
Teicoplanin is poorly absorbed after oral administration but is 90% bioavailable when administered intramuscularly.
n3:affectedOrganism
Gram-positive Bacteria
n3:casRegistryNumber
61036-62-2
n3:category